The Science of HPV

It is a common misconception that HPV is part of the herpesvirus group. It is not. The word "papilloma" refers to the wart-like growths some HPV strains cause — it comes from the Latin for nipple (papilla). The Papillomaviridae family is ancient and distinct, having co-evolved with vertebrates separately from the Herpesviridae. While both herpes simplex viruses and HPV can infect the genital mucosa and both can persist in the host, the comparison ends there. HPV does not travel to the nervous system, does not establish neuronal latency, and its mechanism of persistence and pathogenesis is entirely different.

HPV has evolved a remarkably elegant replication strategy tied directly to how squamous epithelial cells differentiate. The virus cannot replicate in fully differentiated cells — it must enter basal cells (the dividing stem-like cells at the base of the epithelium) through microabrasions in the mucosa.

Once inside a basal cell, HPV maintains its genome as a low-copy episome (free circular DNA, not integrated into the chromosome) and replicates modestly as the cell divides — essentially hitching a ride on the host cell's normal DNA replication. As the infected cell differentiates and migrates toward the epithelial surface, HPV amplifies its genome to very high copy numbers and assembles new virions — a process that only completes in fully differentiated cells. This means HPV replicates entirely within the normal programme of epithelial differentiation, and the immune system has limited opportunity to see the virus during active replication.

Approximately 90% of HPV infections are cleared by the immune system within 1–2 years. The primary defence is cell-mediated immunity — cytotoxic T lymphocytes recognising HPV protein fragments (particularly from the E6 and E7 early proteins) displayed on the surface of infected epithelial cells. People who fail to mount an effective T-cell response — including those who are immunosuppressed, smokers (whose cervical immunity is impaired), and possibly those with certain HLA gene variants — are at significantly higher risk of persistent infection. It is persistent infection with a high-risk HPV type, not transient infection, that creates cancer risk.

The oncogenic potential of high-risk HPV strains is concentrated in two early viral proteins: E6 and E7. Their targets are two of the most fundamental tumour suppressors in the human genome:

• E6 targets p53: p53 is the "guardian of the genome" — a transcription factor that detects DNA damage and either halts the cell cycle to allow repair or triggers apoptosis (programmed cell death) if the damage is too severe. The HPV E6 protein recruits a cellular enzyme called E6-AP ubiquitin ligase, which tags p53 for proteasomal degradation. With p53 absent, cells with DNA damage continue dividing rather than dying — mutations accumulate unopposed.
• E7 targets pRb: The retinoblastoma protein (pRb) is a key brake on cell division — it normally sequesters the transcription factor E2F, preventing cells from entering the cell cycle. The HPV E7 protein binds directly to pRb and forces it to release E2F, driving continuous cell proliferation even in cells that should have stopped dividing. High-risk HPV E7 binds pRb with approximately 10-fold higher affinity than low-risk HPV E7 — explaining much of the difference in oncogenic potential between HPV types.

Cancer does not develop immediately from E6/E7 expression. The transformation from normal cell to cancer cell requires additional genomic events over years. A critical step is integration of the HPV genome into the host chromosome — disrupting the viral E2 gene (which normally suppresses E6/E7) and causing E6/E7 to be expressed constitutively at high levels. Over years, cells with this integrated HPV and continuous E6/E7 expression accumulate further mutations — eventually achieving the full cancer phenotype.

Among high-risk HPV types, HPV 16 and 18 account for approximately 70% of cervical cancers. This is partly due to their prevalence, but also to specific molecular properties. HPV 16 is particularly associated with squamous cell carcinoma (the more common cervical cancer type) and has E7 protein variants with especially high pRb-binding affinity. HPV 18 is disproportionately associated with adenocarcinoma of the cervix — a less common but harder-to-screen-for cancer that arises from glandular cells. HPV 16 is also the dominant type in oropharyngeal cancers — a rapidly rising cancer driven by oral HPV, associated with oral sex, for which the demographic and biological risk factors are distinct from cervical cancer.

The HPV vaccines (Gardasil 9 covers types 6, 11, 16, 18, 31, 33, 45, 52, 58) use virus-like particles (VLPs) — hollow shells made of the HPV L1 major capsid protein, assembled without any viral DNA or E6/E7 proteins. VLPs are structurally identical to the outside of the HPV virion, making them highly immunogenic, but they are completely non-infectious. The immune response generated (particularly high-titre neutralising IgG antibodies) prevents the initial infection of basal cells. Crucially, vaccine-induced antibody concentrations at the cervical mucosa are substantially higher than those generated by natural infection. This is why vaccination before any sexual exposure is so effective — and why it offers less protection after infection has already occurred with a vaccine-covered type.